tbuckley/cabot-search huggingface dataset:
Abstract 17212: 30-day All-cause Readmission is Associated With a Significantly Higher Subsequent All-cause Mortality and Costly Readmissions Among Older Medicare Beneficiaries Hospitalized for Heart Failure
Authors: Cherinne Arundel, Rahul Khosla, Charles Faselis, Charity J Morgan, Sijian Zhang, Marc Blackman, Ross D Fletcher, Wen-Chih Wu, Javed Butler, Gregg C Fonarow, Prakash Deedwania, Michel White, Wilbert S Aronow, Gerasimos S Filippatos, Stefan D Anker, Ali Ahmed, Richard M Allman
Journal: Circulation (2015)

Background: Among ambulatory patients with heart failure (HF), hospital admission is associated with higher subsequent mortality. HF is the leading cause of 30-day all-cause readmission, reduction of which is a goal of the Affordable Care Act. We examined the association of 30-day all-cause readmission with subsequent all-cause mortality in a propensity-matched cohort of hospitalized HF patients. Methods: Of the 8049 Medicare beneficiaries hospitalized for HF and discharged alive from 106 U.S. hospitals (1998-2001), 7578 were alive 30-day post-discharge, of which 1519 had 30-day all-cause readmission. Using propensity scores for 30-day all-cause readmission, we assembled a matched cohort of 1516 pairs of patients with and without 30-day all-cause readmission, balanced on 34 baseline characteristics. Results: During 2-12 months of post-discharge follow-up, all-cause mortality occurred in 41% and 27% of matched patients with and without 30-day all-cause readmission, respectively (HR, 1.68; 95% CI, 1.48-1.90; p&lt;0.001; Figure). During a mean post-index follow up of 3 (max 9) years, patients with 30-day all-cause readmissions (vs. without) had higher total of post-index readmissions (mean, 6.9 vs 5.1; p&lt;0.001), longer cumulative length of stay (mean, 51 vs 43 days; p&lt;0.001), and higher charges (mean, $129,175 vs. $114,787; p=0.012) and payments (mean, $38,972 vs. $34,025; p=0.001) from those readmissions. Conclusions: Among hospitalized patients with HF 30-day all-cause readmission is associated with higher subsequent mortality, number of readmissions and costs, and longer cumulative length of stay.
P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
Authors: P. Cheema, G. Liu, R. Burkes, S. Owen, J. Yu, D. Hao, J. Rothenstein, S. Martel, M. Iqbal, R. Juergens, W. Lam, J. Laskin
Journal: Journal of Thoracic Oncology (2018)
Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future
Authors: Andrew J Boyle, Michael C Sklar, James J McNamee, Daniel Brodie, Arthur S Slutsky, Laurent Brochard, Daniel F McAuley, D Abrams, A Combes, E Fan, J Fraser, C Hodgson, N Patroniti, A Pesenti, R Mac Sweeney, J Manacebo, T Mueller, T Pham, M Ranieri, M Schmidt, K Shekar
Journal: The Lancet Respiratory Medicine (2018)
P2.01-04 Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
Authors: A. Ali, G. Singh Tamber, S. Camilleri-Broet, V. Cohen, J. Spicer, H. Wang, G. Chong, M. Munazzit, C. Rousseau, W. Sateren, M. Fernandez, G. Kasymjanova, S. Owen, A. Spatz, L. Van Kempen, J. Agulnik
Journal: Journal of Thoracic Oncology (2018)
Did Medicaid Expansion Reduce Mortality Among Patients Initiating Dialysis for Irreversible Kidney Failure?
Authors: Kevin F. Erickson, Vivian Ho, Wolfgang C. Winkelmayer
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial
Authors: A. Curioni, E. Felip, U. Dafni, M.-A. Molina, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. Ponce, E. Carcereny, M. Früh, M. Pless, S. Popat, S. Cuffe, N. Karachaliou, R. Kammler, M. Kassapian, H. Roschitzki-Voser, R.A. Stahel, R. Rosell
Journal: Annals of Oncology (2018)
Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: K. Miller, D. Heinrich, J.M. O’Sullivan, J. Carles, M. Wirth, S. Nilsson, L. Huang, J. Kalinovsky, A. Heidenreich, F. Saad
Journal: Annals of Oncology (2018)
MA21.07 A Nation-Wide Population-Based Mapping of Targetable Alterations in Smoking-Independent Lung Cancer
Authors: A. Salomonsson, A. Patthey, C. Reuterswärd, M. Jönsson, J. Botling, H. Brunnström, A. Hussein, N. Monsef, C. Ortiz-Villalon, B. Bergman, L. De Petris, K. Lamberg, A. Vikström, G. Wagenius, A. Behndig, E. Brandén, M. Johansson, H. Koyi, J. Staaf, M. Planck
Journal: Journal of Thoracic Oncology (2018)
P1.01-107 The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Authors: X. Si, L. Zhang, H. Wang, X. Zhang, M. Wang, B. Han, K. Li, Q. Wang, J. Shi, Z. Wang, Y. Cheng, J. He, Y. Shi, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li, Y. Chen, J. Zhou, D. Wang
Journal: Journal of Thoracic Oncology (2018)
Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
Authors: Andrea C Tricco, Wasifa Zarin, Roberta Cardoso, Areti-Angeliki Veroniki, Paul A Khan, Vera Nincic, Marco Ghassemi, Rachel Warren, Jane P Sharpe, Andrea V Page, Sharon E Straus
Journal: BMJ (2018)

Abstract Objective To compare the efficacy, effectiveness, and safety of the herpes zoster live attenuated vaccine with the herpes zoster adjuvant recombinant subunit vaccine or placebo for adults aged 50 and older. Design Systematic review with bayesian meta-analysis and network meta-analysis. Data sources Medline, Embase, and Cochrane Library (inception to January 2017), grey literature, and reference lists of included studies. Eligibility criteria for study selection Experimental, quasi-experimental, and observational studies that compared the live attenuated vaccine with the adjuvant recombinant subunit vaccine, placebo, or no vaccine in adults aged 50 and older. Relevant outcomes were incidence of herpes zoster (primary outcome), herpes zoster ophthalmicus, post-herpetic neuralgia, quality of life, adverse events, and death. Results 27 studies (22 randomised controlled trials) including 2 044 504 patients, along with 18 companion reports, were included after screening 2037 titles and abstracts, followed by 175 full text articles. Network meta-analysis of five randomised controlled trials found no statistically significant differences between the live attenuated vaccine and placebo for incidence of laboratory confirmed herpes zoster. The adjuvant recombinant subunit vaccine, however, was statistically superior to both the live attenuated vaccine (vaccine efficacy 85%, 95% credible interval 31% to 98%) and placebo (94%, 79% to 98%). Network meta-analysis of 11 randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more adverse events at injection sites than the live attenuated vaccine (relative risk 1.79, 95% credible interval 1.05 to 2.34; risk difference 30%, 95% credible interval 2% to 51%) and placebo (5.63, 3.57 to 7.29 and 53%, 30% to 73%, respectively). Network meta-analysis of nine randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more systemic adverse events than placebo (2.28, 1.45 to 3.65 and 20%, 6% to 40%, respectively). Conclusions Using the adjuvant recombinant subunit vaccine might prevent more cases of herpes zoster than using the live attenuated vaccine, but the adjuvant recombinant subunit vaccine also carries a greater risk of adverse events at injection sites. Protocol registration Prospero CRD42017056389.
P2.06-17 Real-World Accuracy of Malignant Pleural Mesothelioma (MPM) Preoperative Magnetic Resonance Imaging (MRI) for Staging the Diaphragm.
Authors: S. Katz, S. Mcnulty, K. Cengel, E. Alley, S. Singhal
Journal: Journal of Thoracic Oncology (2018)
P2.11-20 Lung EpiCheck TM - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer
Authors: J. Chorostowska-Wynimko, I. Horváth, D. Shitrit, V. Eisenberg, D. Stav, D. Levy Faber, P. Rudzinski, M. Jansen, Y. Raviv, V. Panagoulias, G. Izbicki, O. Ronen, A. Goldhaber, R. Moalem, N. Arber, R. Shahien, I. Haas, M. Gaga
Journal: Journal of Thoracic Oncology (2018)
Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)
Authors: S. Daigle, S. Stacchiotti, P. Schöffski, V. Villalobos, G. Cote, R. Chugh, T.W.-W. Chen, T. Jahan, E.T. Loggers, A. Italiano, A. Gupta, M. Agulnik, S. Attia, R.L. Jones, B.A. van Tine, G.D.D. Demetri, A. Clawson, M. Roche, S. Blakemore, M. Gounder
Journal: Annals of Oncology (2018)
Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B
Authors: S. Yuki, K. Shinozaki, T. Kashiwada, T. Kusumoto, M. Iwatsuki, H. Satake, S. Tokunaga, Y. Emi, A. Makiyama, Y. Kawamoto, Y. Komatsu, M. Shimokawa, H. Saeki, E. Oki, H. Baba, Y. Maehara
Journal: Annals of Oncology (2018)
Phylotranscriptomic Insights into the Diversification of Endothermic<i>Thunnus</i>Tunas
Authors: Adam G Ciezarek, Owen G Osborne, Oliver N Shipley, Edward J Brooks, Sean R Tracey, Jaime D McAllister, Luke D Gardner, Michael J E Sternberg, Barbara Block, Vincent Savolainen
Journal: Molecular Biology and Evolution (2018)

Birds, mammals, and certain fishes, including tunas, opahs and lamnid sharks, are endothermic, conserving internally generated, metabolic heat to maintain body or tissue temperatures above that of the environment. Bluefin tunas are commercially important fishes worldwide, and some populations are threatened. They are renowned for their endothermy, maintaining elevated temperatures of the oxidative locomotor muscle, viscera, brain and eyes, and occupying cold, productive high-latitude waters. Less cold-tolerant tunas, such as yellowfin tuna, by contrast, remain in warm-temperate to tropical waters year-round, reproducing more rapidly than most temperate bluefin tuna populations, providing resiliency in the face of large-scale industrial fisheries. Despite the importance of these traits to not only fisheries but also habitat utilization and responses to climate change, little is known of the genetic processes underlying the diversification of tunas. In collecting and analyzing sequence data across 29,556 genes, we found that parallel selection on standing genetic variation is associated with the evolution of endothermy in bluefin tunas. This includes two shared substitutions in genes encoding glycerol-3 phosphate dehydrogenase, an enzyme that contributes to thermogenesis in bumblebees and mammals, as well as four genes involved in the Krebs cycle, oxidative phosphorylation, β-oxidation, and superoxide removal. Using phylogenetic techniques, we further illustrate that the eight Thunnus species are genetically distinct, but found evidence of mitochondrial genome introgression across two species. Phylogeny-based metrics highlight conservation needs for some of these species.
OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.
Authors: F. Hu, J. Xu, B. Zhang, C. Li, W. Nie, P. Gu, P. Hu, H. Wang, Y. Zhang, Y. Shen, S. Wang, B. Han, X. Zhang
Journal: Journal of Thoracic Oncology (2018)
MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
Authors: A. Dingemans, L. Hendriks, T. Berghmans, A. Levy, B. Hasan, C. Faivre-Finn, M. Giaj Levra, N. Giaj-Levra, N. Girard, L. Greillier, S. Lantuejoul, J. Edwards, M. O'Brien, M. Reck, E. Smit, P. Van Schil, P.E. Postmus, S. Ramella, Y. Lievens, M. Gaga, N. Peled, G. Scagliotti, S. Senan, L. Paz-Ares, M. Guckenberger, F. Mcdonald, S. Ekman, T. Cufer, H. Gietema, M. Infante, R. Dziadziuszko, B. Besse, S. Novello
Journal: Journal of Thoracic Oncology (2018)
Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer
Authors: Simona Camorani, Billy Samuel Hill, Francesca Collina, Sara Gargiulo, Maria Napolitano, Monica Cantile, Maurizio Di Bonito, Gerardo Botti, Monica Fedele, Antonella Zannetti, Laura Cerchia
Journal: Theranostics (2018)

While the overall mortality for breast cancer has recently declined, management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and the lack of targeted therapies. Genomic profiling studies highlighted the high level of heterogeneity of this cancer, which comprises different subtypes with unique phenotypes and response to treatment. Platelet-derived growth factor receptor β (PDGFRβ) is an established mesenchymal/stem cell-specific marker in human glioblastoma and, as recently suggested, it may uniquely mark breast cancer cells with stem-like characteristics and/or that have undergone epithelial-mesenchymal transition. Methods: Immunohistochemical analysis for PDGFRβ expression was performed on a human TNBC tissue microarray. Functional assays were conducted on mesenchymal-like TNBC cells to investigate the effect of a previously validated PDGFRβ aptamer on invasive cell growth in three-dimensional culture conditions, migration, invasion and tube formation. The aptamer was labeled with a near-infrared (NIR) dye and its binding specificity to PDGFRβ was assessed both in vitro (confocal microscopy and flow cytometry analyses) and in vivo (fluorescence molecular tomography in mice bearing TNBC xenografts). A mouse model of TNBC lung metastases formation was established and NIR-labeled PDGFRβ aptamer was used to detect lung metastases in mice untreated or intravenously injected with unlabeled aptamer. Results: Here, we present novel data showing that tumor cell expression of PDGFRβ identifies a subgroup of mesenchymal tumors with invasive and stem-like phenotype, and propose a previously unappreciated role for PDGFRβ in driving TNBC cell invasiveness and metastases formation. We show that the PDGFRβ aptamer blocked invasive growth and migration/invasion of mesenchymal TNBC cell lines and prevented TNBC lung metastases formation. Further, upon NIR-labeling, the aptamer specifically bound to TNBC xenografts and detected lung metastases. Conclusions: We propose PDGFRβ as a reliable biomarker of a subgroup of mesenchymal TNBCs with invasive and stem-like phenotype as well as the use of the PDGFRβ aptamer as a high efficacious tool for imaging and suppression of TNBC lung metastases. This study will allow for the significant expansion of the current repertoire of strategies for managing patients with more aggressive TNBC.
Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97
Authors: T. Decker, C. Denkert, K. Lübbe, V. Müller, C. Mundhenke, J. Furlanetto, M. Schmidt, M. Thill, V. Tierbach, F. Seither, S. Loibl
Journal: Annals of Oncology (2018)
Two Methods for Mapping and Visualizing Associated Data on Phylogeny Using <i>Ggtree</i>
Authors: Guangchuang Yu, Tommy Tsan-Yuk Lam, Huachen Zhu, Yi Guan
Journal: Molecular Biology and Evolution (2018)

Ggtree is a comprehensive R package for visualizing and annotating phylogenetic trees with associated data. It can also map and visualize associated external data on phylogenies with two general methods. Method 1 allows external data to be mapped on the tree structure and used as visual characteristic in tree and data visualization. Method 2 plots the data with the tree side by side using different geometric functions after reordering the data based on the tree structure. These two methods integrate data with phylogeny for further exploration and comparison in the evolutionary biology context. Ggtree is available from http://www.bioconductor.org/packages/ggtree.
The health of forced migrants
Authors: Angela Burnett, Tracy Ndovi
Journal: BMJ (2018)

### What you need to know

> “If you have never been tortured, been forced to make a dangerous journey, or leave your child, you may not fully understand what it does to a human being.”

The “cultural bereavement of exile”1 is the loss of social structures, cultural values, community rituals, relationships, and material features experienced by forced migrants. Meeting the healthcare needs of those affected can help achieve safety and rehabilitation.

Globally, the number of forced migrants is estimated at 68.5 million.2 Most of these people remain close to their home country; those with access to resources may travel further. Countries hosting the greatest numbers of migrants are Turkey (3.5 million), Pakistan (1.4 million), Uganda (1.4 million), Lebanon (998 900), Iran (979 400), Germany (970 400), Bangladesh (932 200), and Sudan (906 600).3

Forced migrants include asylum seekers, refugees, and people who have experienced torture, armed conflict, and human trafficking (for slavery or sexual exploitation). They are at risk of several physical and mental illnesses. Management often requires approaches that are different from those used for the rest of the population.

This article provides an overview of the healthcare needs of migrants who have been forced to leave their home countries. It aims to offer guidance to, and raise awareness among, health workers caring for them.

### Sources and selection criteria

Most of the information in this article is based on our own personal and clinical experience, supported by references, which are listed.

Additional educational …
P2.16-17 Hypo-Fractionated Accelerated Radiotherapy in Central Early Non-Small Cell Lung Cancer: Leeds Cancer Centre Experience
Authors: T. Janjua, M. Arunsingh, K. Clarke, P. Dickinson, K. Franks, P. Murray, M. Snee, M. Teo, P. Jain
Journal: Journal of Thoracic Oncology (2018)
Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer running head: Revisiting estrogen positive tumors in 8th AJCC staging era
Authors: J.M. Ryu, S.K. Lee, J.E. Lee, S.J. Nam, J. Yu, H.J. Choi, I. Kim, S.W. Kim
Journal: Annals of Oncology (2018)
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Authors: A. Jouinot, B. Royer, S. Moeung, E. Chatelut, A. Bellesoeur, G. Assié, A. Thomas-Schoemann, J. Bertherat, F. Goldwasser, B. Blanchet
Journal: Annals of Oncology (2018)
Peyer’s patch myeloid cells infection by <i>Listeria</i> signals through gp38+ stromal cells and locks intestinal villus invasion
Authors: Olivier Disson, Camille Blériot, Jean-Marie Jacob, Nicolas Serafini, Sophie Dulauroy, Grégory Jouvion, Cindy Fevre, Grégoire Gessain, Pierre Thouvenot, Gérard Eberl, James P. Di Santo, Lucie Peduto, Marc Lecuit
Journal: The Journal of Experimental Medicine (2018)

The foodborne pathogen Listeria monocytogenes (Lm) crosses the intestinal villus epithelium via goblet cells (GCs) upon the interaction of Lm surface protein InlA with its receptor E-cadherin. Here, we show that Lm infection accelerates intestinal villus epithelium renewal while decreasing the number of GCs expressing luminally accessible E-cadherin, thereby locking Lm portal of entry. This novel innate immune response to an enteropathogen is triggered by the infection of Peyer's patch CX3CR1+ cells and the ensuing production of IL-23. It requires STAT3 phosphorylation in epithelial cells in response to IL-22 and IL-11 expressed by lamina propria gp38+ stromal cells. Lm-induced IFN-γ signaling and STAT1 phosphorylation in epithelial cells is also critical for Lm-associated intestinal epithelium response. GC depletion also leads to a decrease in colon mucus barrier thickness, thereby increasing host susceptibility to colitis. This study unveils a novel innate immune response to an enteropathogen, which implicates gp38+ stromal cells and locks intestinal villus invasion, but favors colitis.
Bottlenecks for genome-edited crops on the road from lab to farm
Authors: Armin Scheben, David Edwards
Journal: Genome biology (2018)

Gene discovery and government regulation are bottlenecks for the widespread adoption of genome-edited crops. We propose a culture of sharing and integrating crop data to accelerate the discovery and prioritization of candidate genes, as well as a strong engagement with governments and the public to address environmental and health concerns and to achieve appropriate regulatory standards.
P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer
Authors: O. Icht, L. Domachevsky, D. Groshar, E. Dudnik, O. Rotem, N. Peled, D. Reinhorn, O. Jacobi, T. Shochat, H. Bernstine, A. Zer
Journal: Journal of Thoracic Oncology (2018)
Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): A FIRE-3 analysis
Authors: D.P. Modest, V. Heinemann, G. Folprecht, T. Denecke, J. Pratschke, H. Lang, M. Bemelmans, T. Becker, M. Rentsch, D. Seehofer, C. Bruns, B. Gebauer, S. Held, U. Neumann, I. Ricard
Journal: Annals of Oncology (2018)
Prospective multicenter feasibility study of laparoscopic sentinel basin dissection after endoscopic submucosal dissection for early gastric cancer
Authors: K.W. Ryu, B.W. Eom, H.M. Yoon, Y.-W. Kim, J.S. Min, G.S. Cho, I. Cho, Y.J. Lee, J.-H. Park, H. Hur, Y.K. Park, O. Jeong, M.R. Jung, J.H. Lee, J.Y. An
Journal: Annals of Oncology (2018)
Influence of primary tumour sidedness on survival after upfront primary tumour resection (PTR) in synchronous metastatic colon cancer (mCC)
Authors: K.L. van Rooijen, S.A. Kurk, D.E.W. van der Kruijssen, S. Elias, A.M. May, A. Cats, G.-J.M. Creemers, F.L.G. Erdkamp, O.J. Loosveld, C.J. Rodenburg, P.J. Tanis, G.R. Vink, J.H.W. de Wilt, C.J.A. Punt, M. Koopman
Journal: Annals of Oncology (2018)
Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis
Authors: Debra T. Choi, Hye-Chung Kum, Sulki Park, Robert L. Ohsfeldt, Yu Shen, Neehar D. Parikh, Amit G. Singal
Journal: Clinical Gastroenterology and Hepatology (2018)
MA08.02 Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations
Authors: O. Arrieta, F. Maldonado, L. Ramírez-Tirado, F. Barron, Y. Campos-Salgado, M. Blake, A. Cardona, J. De La Garza
Journal: Journal of Thoracic Oncology (2018)